Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Beam Therapeutics's total assets was $1.39B at Jun 30, 2026. For fiscal 2025 it was $1.48B, up 34.2% from the year before. The highest annual figure on record is $1.48B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48B | +34.2% |
| FY2024 | Dec 31, 2024 | $1.10B | -24.4% |
| FY2023 | Dec 31, 2023 | $1.46B | +8.8% |
| FY2022 | Dec 31, 2022 | $1.34B | -9.0% |
| FY2021 | Dec 31, 2021 | $1.47B | +226.4% |
| FY2020 | Dec 31, 2020 | $451.68M | +189.4% |
| FY2019 | Dec 31, 2019 | $156.10M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.39B | -0.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.48B | +0.9% |
| Q4 FY2025 | Dec 31, 2025 | $1.48B | +34.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.31B | +11.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.39B | +10.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.47B | +7.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.10B | -24.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.17B | -9.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.26B | -6.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.36B | +2.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.46B | +8.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.29B | -4.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.35B | -4.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.33B | -8.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.34B | -9.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.35B | +16.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.42B | +58.8% |
| Q1 FY2022 | Mar 31, 2022 | $1.45B | +109.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.47B | +226.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.16B | +315.6% |
| Q2 FY2021 | Jun 30, 2021 | $893.08M | +197.7% |
| Q1 FY2021 | Mar 31, 2021 | $693.24M | +114.9% |
| Q4 FY2020 | Dec 31, 2020 | $451.68M | +189.4% |
| Q3 FY2020 | Sep 30, 2020 | $278.27M | – |
| Q2 FY2020 | Jun 30, 2020 | $299.98M | – |
| Q1 FY2020 | Mar 31, 2020 | $322.64M | – |
| Q4 FY2019 | Dec 31, 2019 | $156.10M | – |
See a number that looks wrong?